updated 11/30/2010 10:46:28 AM ET 2010-11-30T15:46:28

VENICE, Fla., Nov. 30, 2010 (GLOBE NEWSWIRE) -- SinoFresh® HealthCare, Inc., (Pink Sheets:SFSH) announces several significant changes to the corporate management team including the election of Thomas Fitzgerald as Chairman of the Board of Directors and the naming of David R. Olund as President & CEO. The changes were made as part of a broad based, ongoing corporate restructuring.

Mr. Fitzgerald, the new Chairman of the Board, has more than 25 years of experience in the biopharmaceutical industry. As an industry consultant and senior executive, he has provided strategic advice for a range of early stage companies and turnaround candidates as well as working with and for well established domestic and multinational businesses. He has also worked with a number of research based institutions including the University of Rochester, the Scripps Institute and Thomas Jefferson University on the generation and growth of spin out life science business from their intellectual property. Mr. Fitzgerald has been a member of the SinoFresh Board since 2008.

Mr. Fitzgerald has also held seats on the Boards of Directors for a number of public and private entities. During his career, he has been responsible for the development, regulatory and marketing strategies, government relations, and intellectual property matters for biopharmaceutical companies. He has held senior executive positions for a number of both large and small companies, in the USA and Europe. Mr. Fitzgerald will be working closely with Mr. David Olund, the Company's new CEO to establish SinoFresh HealthCare, Inc. as an industry leader and a global presence.

Mr. Olund, the new CEO, has over 30 years of domestic and international experience in the financial services industry. He has had corporate and marketing relationships with companies such as Sun Life of Canada, The CNA Companies, Western Reserve Life Assurance, New York Life, LifeUSA Traveler Insurance Company and Shearson/American Express as well as other companies. Mr. Olund has held the Registered Securities Principal designation in the past including the position of President, CEO and Chief Compliance Officer of an NASD member securities firm. During the last 15 years, his financial consulting work has encompassed assignments for public and private companies, specializing in alternative finance markets and corporate development in the United States, as well as doing significant work in Europe, Asia and Latin America for private multi-national clients.

Mr. Fitzgerald commented that, "David Olund's experience, passion and know-how will be indispensable to SinoFresh in growing the company's business. David has a proven record of initiating and achieving favorable results form the kinds of steps that will be essential in achieving our ambitious plans to build the business and establish the long term shareholder value that follows from the growth of the business."

Mr. Olund comments, "I am proud to be serving the future needs of the SinoFresh HealthCare business. I particularly look forward to a bright and promising future on behalf of our shareholders. I believe that with the combined backgrounds of our senior management team and our Board of Directors, will enable us to fully develop our breakthrough technologies in antiseptic upper respiratory and topical therapies. SinoFresh is very well positioned to become a significant player in the healthcare industry." Mr. Olund was also elected to the Board of Directors as part of the management realignment. Mr. Fitzgerald and Mr. Olund replace the out-going Chairman and CEO, Charles Fust, who has left the company.

SinoFresh HealthCare, Inc. is a publicly traded company (Pink Sheets:SFSH) based in Venice, Florida, that manufactures and distributes nasal, oral and topical antiseptic germ-killing products. SinoFresh products are marketed and distributed globally through a network of strategic wholesale and retail partners. SinoFresh Healthcare Inc's, premier product, SinoFresh Antiseptic Homeopathic Nasal spray has in laboratory tests shown effective antiseptic capability against a variety of pathogens such as MRSA, E-Coli, H1N1 and a broad range of other viruses, molds, fungi and bacteria. 

For more information please contact our Investor Relations department at 941.375.8174

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Our forward-looking statements express our current expectations or forecasts of possible future results or events, including projections of future performance, statements of management's plans and objectives, future contracts, and forecasts of trends and other matters. Forward-looking statements speak only as of the date of this filing, and we undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur. You can identify these statements by the fact that they do not relate strictly to historic or current facts and often use words such as "anticipate", "estimate", "expect", "believe", "will likely result", "outlook", "project" and other words and expressions of similar meaning. No assurance can be given that the results in any forward-looking statements will be achieved and actual results could be affected by one or more factors, which could cause them to differ materially. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com